Modern machine learning methods deliver strong predictive performance for bioprocess datasets, supporting productivity improvement and deeper process understanding. In this session, Seongjin Kim of Samsung Biologics demonstrates how XGBoost is used for prediction and how Bayesian optimization efficiently tunes model settings for robust performance on a bioprocess dataset. He will also show the use of Shapley values—an explainable AI (XAI) approach—to identify the process variables most strongly associated with productivity outcomes. Attendees will learn how these modern, data-driven methods can be applied to drive practical productivity improvements.

When planning a technology transfer, choosing a CDMO partner with deep scientific, operational, and cross‑functional expertise can make all the difference. In this expert panel discussion, Rentschler Biopharma’s experts share real‑world lessons from supporting complex programs through phase‑appropriate development, scale‑up, and cGMP manufacturing. They offer a transparent look at what truly drives a smooth, efficient, and reliable tech‑transfer experience.

Key Insights:

• Essential elements of a successful tech transfer

Core scientific and operational considerations as processes advance to cGMP production. 

• What to evaluate before initiating a transfer

How early alignment, molecule understanding, and process robustness reduce downstream complexity and risk.

• Pitfalls and blind spots

Practical insights into where transfers commonly encounter challenges—and how experienced teams plan ahead to mitigate them.

• Why strong execution creates lasting value

How clear planning, cross functional coordination, and predictable scale-up contribute to reliable timelines and overall project success.

Why attend?

Whether this is your first tech transfer or you’re optimizing a new phase of development, this panel offers grounded, experience driven guidance that can help you prepare effectively. Expect real examples and practical takeaways you can directly apply to your next transfer.

Polymer-based excipients, including lactide-glycolide and lactic acid-glycolic acid polymers (PLGs and PLGAs, collectively referred to as LG polymers), play a vital role in enhancing controlled drug release, delivery and bioavailability—particularly in long-acting injectable (LAI) formulations. While these excipients offer multiple benefits, the industry faces challenges in excipient selection due to naming differences, formulation complexity, and raw material variability.

Join this webinar as USP experts take a deep dive into standards and solutions that support quality and performance across the drug lifecycle and present: 

• • USP’s integrated framework to LG polymer excipient naming and characterization 
• • Review of USP offerings for LG polymer USP standards, including monographs, general chapters, stimuli articles, and reference standards 
• • Overview of USP’s emerging solutions, including analytical reference materials (ARMs), case studies, education courses, technical notes, and peer-reviewed journal articles 

By showcasing this integrated strategy, USP aims to empower stakeholders with these standards and solutions to navigate the complexities of excipient naming, selection and characterization for LAIs.